Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Jun 28;6(6):e011801.
doi: 10.1136/bmjopen-2016-011801.

Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE)

Affiliations
Randomized Controlled Trial

Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE)

Neil O'Gorman et al. BMJ Open. .

Abstract

Introduction: Pre-eclampsia (PE) affects 2-3% of all pregnancies and is a major cause of maternal and perinatal morbidity and mortality. Prophylactic use of low-dose aspirin in women at risk for PE may substantially reduce the prevalence of the disease. Effective screening for PE requiring delivery before 37 weeks (preterm PE) can be provided by a combination of maternal factors, uterine artery Doppler, mean arterial pressure, maternal serum pregnancy-associated plasma protein A and placental growth factor at 11-13 weeks' gestation, with a detection rate of 75% at a false-positive rate of 10%. We present a protocol (V.6, date 25 January 2016) for the ASpirin for evidence-based PREeclampsia prevention (ASPRE) trial, which is a double-blinded, placebo-controlled, randomised controlled trial (RCT) that uses an effective PE screening programme to determine whether low-dose aspirin given to women from 11 to 13 weeks' gestation will reduce the incidence of preterm PE.

Methods and analysis: All eligible women attending for their first trimester scan will be invited to participate in the screening study for preterm PE. Those found to be at high risk of developing preterm PE will be invited to participate in the RCT. Further scans will be conducted for assessment of fetal growth and biomarkers. Pregnancy and neonatal outcomes will be collected and analysed. The first enrolment for the pilot study was in April 2014. As of April 2016, 26 670 women have been screened and 1760 recruited to the RCT. The study is registered on the International Standard Randomised Controlled Trial Number (ISRCTN) registry.

Trial registration number: ISRCTN13633058.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of participants in the screening study and the randomised controlled trial. *Clinical visits at 19–24 and 30–37 weeks will only be performed on screen-negative participants at sites where a scan is performed by the fetal medicine unit as part of the routine clinical care pathway at either of these times. FGR, fetal growth restriction; PE, pre-eclampsia.

References

    1. Witlin GA, Saade GR, Mattar FM et al. . Predictors of neonatal outcome in women with severe pre-eclampsia or eclampsia between 24 and 33 weeks’ gestation. Am J Obstet Gynecol 2000;182:607–11. 10.1067/mob.2000.104224 - DOI - PubMed
    1. Irgens HU, Reisaeter L, Irgens LM et al. . Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001;323:1213–17. 10.1136/bmj.323.7323.1213 - DOI - PMC - PubMed
    1. von Dadelszen P, Magee LA, Roberts JM. Subclassification of pre-eclampsia. Hypertens Pregnancy 2003;22:143–8. 10.1081/PRG-120021060 - DOI - PubMed
    1. Yu CK, Khouri O, Onwudiwe N et al. . Prediction of pre-eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2008;31:310–13. 10.1002/uog.5252 - DOI - PubMed
    1. Akolekar R, Syngelaki A, Sarquis R et al. . Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011;31:66–74. 10.1002/pd.2660 - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data